Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema

NCT01882712 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Erythema

Interventions

DRUG: CD07805/47 Gel 0.5%
DRUG: CD07805/47 Gel Placebo

Sponsor

Galderma R&D